shelf(0)

No. 012 · GH & Growth · Growth Hormone

Tesamorelin

EgriftaEgrifta SVEgrifta WRTH9507

S Tier S · Approved how tiers work →
  • FDA approved 2010
  • WADA ✗ S2
Compare Cite
Fingerprint no sequence
Tesamorelin (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER S — Approved by the FDA or EMA for at least one indication.

FDA-approved (Egrifta) to reduce excess abdominal fat in HIV-associated lipodystrophy, based on phase 3 RCTs.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Approved (2010) Egrifta Reduction of excess abdominal fat in adults with HIV and lipodystrophy.
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
03

Overview

An FDA-approved GHRH analog specifically indicated for HIV-associated lipodystrophy. It reduces visceral fat while preserving subcutaneous fat and lean mass.

Research status FDA-approved (Egrifta) for HIV-associated lipodystrophy; robust Phase III clinical trial data

04

Mechanism

Tesamorelin is a synthetic GHRH analog with a trans-3-hexenoic acid modification that increases enzymatic stability. It binds the GHRH receptor on pituitary somatotrophs, stimulating physiological GH release. The resulting GH and IGF-1 elevation promotes visceral adipose lipolysis while preserving subcutaneous fat distribution.

05

Effects reported in research

Reported outcomes, not promises. Some come from controlled human trials; others may be from smaller or preclinical studies — check the studies below.

  • Significant visceral fat reduction
  • Increased IGF-1 to physiological levels
  • Improved lipid profiles
  • Preserved lean body mass
06

Safety & unknowns

FDA-approved (Egrifta) with Phase III safety data. Common side effects: injection site reactions, arthralgia, peripheral edema, myalgia. Contraindicated in active malignancy and pregnancy. Monitor IGF-1 levels during treatment.

Unknowns. Trial safety data apply to the populations, formulations and conditions studied.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

07

Studies [0]

No studies cited for this entry yet.

09

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

10

Cite this entry

$ cite --format=apa

peptidemeta. (2026). Tesamorelin. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/tesamorelin/

$ cite --format=bibtex 
@misc{peptidemeta-tesamorelin,
  title = {Tesamorelin},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/tesamorelin/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open